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Abstract: Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment 
of the hepatitis B virus (HBV) in 2005. In Phase III trials, it showed potent HBV suppression 
with drops of 6- to 7-log copies/mL in HBV DNA at 1 year. In addition, rates of genotypic 
resistance in nucleos(t)ide-naïve patients are low, reaching only 1.2% after 6 years. Safety and 
efficacy have been established in compensated cirrhosis and HIV-coinfected patients. Studies 
in decompensated cirrhosis also show efficacy. Because of potent viral suppression and a large 
genetic barrier to resistance, entecavir is now a first-line choice in most HBV treatment guide-
lines and has become an integral part of the HBV treatment armamentarium.
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Introduction
During the past decade, four new drugs (adefovir, entecavir, telbivudine, and   tenofovir) 
have been approved for the treatment of chronic hepatitis B virus (HBV), joining 
lamivudine as options for treatment. These new additions to the HBV arsenal have 
made decisions about treatment more complex. It has become increasingly important 
for treating physicians to understand the benefits and limitations of each agent as 
they decide on an initial or salvage regimen. This review will describe the efficacy 
of entecavir compared with other available drugs, as well as safety and resistance 
patterns. These issues are important to consider for drug sequencing in patients with 
chronic HBV .
Natural history of hepatitis B
Over 350 million people worldwide are chronically infected with HBV .1 The burden 
of disease is largely geographic, with South-East Asia and Sub-Saharan Africa being 
endemic.1 In these areas, transmission is primarily vertical or during childhood, where 
most infections go on to chronicity.2 In nonendemic areas, such as western Europe and 
the US, transmission is primarily sexual and occurs in early adulthood. When acquired 
later during life in this situation, 95% of acute HBV cases resolve spontaneously.2 
Universal vaccination of infants in both endemic and nonendemic areas will no doubt 
change this epidemiology over the coming decades.
Once chronicity is established, the patient may undergo a period of immunotoler-
ance, where HBV DNA levels are extremely high yet aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) levels are normal.3 There is little to no inflamma-
tion present in the liver. In endemic areas, the immunotolerant period may last years, 
into the third decade of life. In nonendemic areas, however, the immunotolerant period Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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generally is so short as to not be recognized. Following the 
immunotolerant period is the time of immune clearance, or 
active chronic HBV. HBV DNA levels are still high, and 
ALT and AST levels also become elevated as an indication 
of active inflammation of the hepatic tissue. Hepatitis B 
e antigen (HBeAg) is positive. If the patient maintains this 
state for longer than 6 months (distinguishing acute HBV 
from chronic HBV), treatment is indicated.
Some patients will pass through the immune   clearance 
phase without treatment and become inactive carriers of HBV , 
where HBV surface antigen remains positive but HBeAg 
becomes negative and hepatitis B e antibody   (anti-HBe) 
develops. The HBV DNA levels during this time are low or 
undetectable, and AST and ALT levels are normal. In many 
cases, this carrier state persists long term, but, in others, 
HBV can reactivate as chronic “e-antigen-negative” HBV .3 
HBV DNA levels again rise, AST and ALT levels become 
elevated, and treatment is indicated once again. This is a later 
stage in the natural history of disease and can progress to 
cirrhosis more quickly.4 Typically,   e-antigen-negative HBV 
occurs due to a mutation in the precore region that prohibits 
e-antigen from being produced.5
The endpoints for studies of therapeutics in HBV have 
been standardized according to a workshop convened by the 
National Institutes of Health.6 New agents are studied sepa-
rately in e-antigen-positive patients and e-antigen-negative 
patients. For both subgroups, endpoints include virologic 
suppression (drop in HBV DNA), biochemical response 
(normalization of ALT), and histological response (decrease 
in Knodell necroinflammatory score by at least two points 
with no worsening of fibrosis scores). For HBeAg-positive 
patients, additional endpoints of HBeAg loss and HBeAg 
seroconversion (development of anti-HBe) are also included. 
All of these endpoints are surrogate endpoints. More long-
term follow-up is needed to determine whether these agents 
improve mortality or decrease development of end-stage liver 
disease or hepatocellular carcinoma (HCC).
Mechanism and pharmacokinetics  
of entecavir
All HBV therapies interrupt HBV replication by acting as 
nucleos(t)ide analogs. The chemical structure of lamivudine 
is 2′3′-dideoxy-3′-thiacytidine. Adefovir is a nucleotide ana-
log of adenosine monophosphate. Tenofovir is structurally 
similar to adefovir. Telbivudine is a l-nucleoside analog of 
deoxythymidine.
Entecavir is a cyclopentyl guanosine nucleoside analog 
that has selective activity against the HBV polymerase.7 It is 
efficiently phosphorylated to its active triphosphate form 
by host cellular kinases.8 Entecavir blocks HBV replication 
at three essential steps: priming of the HBV polymerase, 
elongation of the DNA strand via reverse transcription, 
and   DNA-dependent plus-strand DNA synthesis and 
  polymerization.9 In contrast, lamivudine shows negligible 
effects on the priming reaction.
In pharmacokinetic studies in healthy subjects, peak plasma 
concentrations of entecavir were reached in 0.5–1.5 hours, 
with steady state reached after 6–10 days of once-daily 
administration.7 The intracellular half-life is approximately 
15 hours. It is predominantly excreted by the kidney with 
urinary recovery of the unchanged drug at steady state rang-
ing from 62% to 73% of the administered dose.7 Because of 
this, entecavir requires dosage   adjustment for patients with 
creatinine clearance less than 50 mL/min, including those on 
dialysis.7 No dosage adjustment is required in liver disease. 
Pharmacokinetic studies have shown that entecavir is not 
a substrate, inhibitor, or inducer of the cytochrome P450 
enzyme system, and therefore the   pharmacokinetics of ente-
cavir are unlikely to be affected by coadminstration of agents 
that are metabolized by, inhibit, or induce these enzymes. 7
Clinical studies of efficacy
Phase I dose-ranging studies of entecavir demonstrated 
rapid and potent dose-related virologic suppression of HBV 
DNA.10,11 Because of shared resistance mutations between 
entecavir and lamivudine, clinical trials evaluated its use in 
both nucleos(t)ide-naïve patients and lamivudine-refractory 
patients. Efficacy was reduced in lamivudine-refractory 
patients harboring mutations in the tyrosine–methionine–
aspartate–aspartate (YMDD) motif of the HBV polymerase; 
thus, a higher dosage of 1 mg daily was selected for devel-
opment in these patients, compared with 0.5 mg/day for 
nucleos(t)ide-naïve patients.
Two multinational Phase III trials were conducted among 
nucleos(t)ide-naïve patients in HBeAg-positive patients12 and 
HBeAg-negative patients,13 both compared with lamivudine 
100 mg daily. A Phase III trial was also carried out in China in a 
mixed population of both HBeAg-positive and HBeAg-  negative 
patients.14 A smaller Phase III study compared entecavir with 
adefovir in patients with baseline HBV DNA levels .8 log 
copies/mL.15 Among HBeAg-positive patients, results at 
48 weeks were similar across all studies with 68%–89% of 
patients achieving ALT normalization, and 58%–74% having 
an undetectable HBV DNA by sensitive polymerase chain reac-
tion (PCR) assay (Table 1). The mean drop in HBV DNA over 
48 weeks was 6–7 log   copies/mL. On all of these parameters, Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
57
entecavir for hepatitis B
T
a
b
l
e
 
1
 
S
u
m
m
a
r
y
 
o
f
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
o
f
 
e
n
t
e
c
a
v
i
r
A
L
T
 
 
n
o
r
m
a
l
i
z
a
t
i
o
n
D
r
o
p
 
i
n
 
H
B
V
 
v
i
r
a
l
 
 
l
o
a
d
 
(
l
o
g
 
c
o
p
i
e
s
/
m
l
)
U
n
d
e
t
e
c
t
a
b
l
e
 
H
B
V
 
D
N
A
 
b
y
 
P
C
R
H
B
e
A
g
 
l
o
s
s
H
B
e
A
g
 
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
H
B
s
A
g
 
l
o
s
s
H
B
s
A
g
 
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
H
i
s
t
o
l
o
g
i
c
a
l
 
 
i
m
p
r
o
v
e
m
e
n
t
N
u
c
l
e
o
s
i
d
e
 
n
a
ï
v
e
,
 
H
B
e
A
g
 
p
o
s
i
t
i
v
e
Y
e
a
r
 
1
 
C
h
a
n
g
 
e
t
 
a
l
1
2
6
8
%
−
6
.
9
6
7
%
2
2
%
2
1
%
2
%
7
2
%
 
L
e
u
n
g
 
e
t
 
a
l
1
5
7
6
%
5
8
%
1
8
%
1
5
%
N
o
t
 
r
e
p
o
r
t
e
d
 
Y
a
o
 
e
t
 
a
l
1
4
8
9
%
−
6
.
0
7
4
%
1
8
%
1
5
%
N
o
t
 
r
e
p
o
r
t
e
d
Y
e
a
r
 
2
 
G
i
s
h
 
e
t
 
a
l
1
6
8
7
%
8
0
%
3
1
%
5
%
2
%
N
u
c
l
e
o
s
i
d
e
 
n
a
ï
v
e
,
 
H
B
e
A
g
 
n
e
g
a
t
i
v
e
Y
e
a
r
 
1
 
L
a
i
 
e
t
 
a
l
1
3
7
8
%
−
5
.
0
9
0
%
7
0
%
 
Y
a
o
 
e
t
 
a
l
1
4
9
4
%
−
5
.
2
2
9
4
%
N
o
t
 
r
e
p
o
r
t
e
d
Y
e
a
r
 
2
 
S
h
o
u
v
a
l
 
e
t
 
a
l
1
7
2
7
%
8
5
%
0
%
L
a
m
i
v
u
d
i
n
e
 
r
e
f
r
a
c
t
o
r
y
Y
e
a
r
 
1
 
C
h
a
n
g
 
e
t
 
a
l
1
0
6
8
%
−
5
.
0
6
2
6
%
1
1
%
4
%
 
S
h
e
r
m
a
n
 
e
t
 
a
l
1
8
6
1
%
−
5
.
1
1
1
9
%
1
0
%
8
%
5
5
%
 
Y
a
o
 
e
t
 
a
l
1
9
8
5
%
−
5
.
0
8
2
7
%
6
%
N
o
t
 
r
e
p
o
r
t
e
d
 
S
u
z
u
k
i
 
e
t
 
a
l
2
0
7
8
%
−
3
.
7
5
3
3
%
1
5
%
6
0
%
Y
e
a
r
 
2
 
S
h
e
r
m
a
n
 
e
t
 
a
l
2
1
8
5
%
−
5
.
9
3
0
%
1
6
%
1
.
4
%
0
.
7
%
 
Y
a
o
 
e
t
 
a
l
2
2
8
0
%
4
7
%
1
3
%
1
1
%
Y
e
a
r
 
3
 
Y
a
o
 
e
t
 
a
l
2
2
6
5
%
5
5
%
1
7
%
1
2
%
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
L
T
,
 
a
l
a
n
i
n
e
 
a
m
i
n
o
t
r
a
n
s
f
e
r
a
s
e
;
 
H
B
e
A
g
,
 
h
e
p
a
t
i
t
i
s
 
B
 
e
 
a
n
t
i
g
e
n
;
 
H
B
s
A
g
,
 
h
e
p
a
t
i
t
i
s
 
B
 
s
u
r
f
a
c
e
 
a
n
t
i
g
e
n
;
 
H
B
v
,
 
h
e
p
a
t
i
t
i
s
 
B
 
v
i
r
u
s
;
 
P
C
R
,
 
p
o
l
y
m
e
r
a
s
e
 
c
h
a
i
n
 
r
e
a
c
t
i
o
n
.
 Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
58
Osborn
T
a
b
l
e
 
2
 
C
o
m
p
a
r
a
t
i
v
e
 
e
f
fi
c
a
c
i
e
s
 
a
t
 
1
 
y
e
a
r
 
o
f
 
a
v
a
i
l
a
b
l
e
 
n
u
c
l
e
o
s
(
t
)
i
d
e
 
a
n
a
l
o
g
s
 
f
o
r
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
o
f
 
h
e
p
a
t
i
t
i
s
 
B
A
L
T
 
 
n
o
r
m
a
l
i
z
a
t
i
o
n
D
r
o
p
 
i
n
 
H
B
V
 
 
D
N
A
 
(
l
o
g
 
c
o
p
i
e
s
/
m
L
)
U
n
d
e
t
e
c
t
a
b
l
e
 
 
H
B
V
 
D
N
A
 
b
y
 
P
C
R
H
B
e
A
g
 
l
o
s
s
H
B
e
A
g
 
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
H
B
s
A
g
 
l
o
s
s
H
B
s
A
g
 
 
s
e
r
o
c
o
n
v
e
r
s
i
o
n
H
i
s
t
o
l
o
g
i
c
a
l
 
 
r
e
s
p
o
n
s
e
H
B
e
A
g
 
p
o
s
i
t
i
v
e
L
a
m
i
v
u
d
i
n
e
2
5
,
2
6
4
1
%
–
7
2
%
3
2
%
1
6
%
–
1
7
%
0
%
–
2
%
0
%
1
4
%
–
3
2
%
A
d
e
f
o
v
i
r
2
7
,
2
8
4
8
%
–
7
9
%
−
3
.
5
2
2
1
%
1
3
%
–
2
4
%
8
%
–
1
2
%
5
3
%
e
n
t
e
c
a
v
i
r
1
2
,
1
4
,
1
5
6
8
%
–
8
9
%
−
6
.
9
5
8
%
–
7
4
%
1
8
%
–
2
2
%
1
5
%
–
2
1
%
2
%
7
2
%
T
e
l
b
i
v
u
d
i
n
e
2
9
–
3
1
7
7
%
–
8
7
%
−
6
.
5
6
6
0
%
–
6
7
%
2
5
%
–
3
0
%
2
2
%
–
2
7
%
6
4
.
7
%
T
e
n
o
f
o
v
i
r
3
2
6
8
%
N
o
t
 
r
e
p
o
r
t
e
d
7
6
%
2
1
%
3
.
2
%
7
4
%
H
B
e
A
g
 
n
e
g
a
t
i
v
e
A
d
e
f
o
v
i
r
3
3
7
2
%
−
5
.
2
3
5
1
%
6
4
%
e
n
t
e
c
a
v
i
r
1
3
,
1
4
7
8
%
–
9
4
%
−
5
.
2
2
9
0
%
–
9
4
%
7
0
%
T
e
l
b
i
v
u
d
i
n
e
3
0
,
3
1
7
4
.
4
%
–
1
0
0
%
−
5
.
5
8
5
%
–
8
8
%
6
6
.
6
%
T
e
n
o
f
o
v
i
r
3
2
7
6
%
N
o
t
 
r
e
p
o
r
t
e
d
9
3
%
0
%
0
%
7
2
%
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
L
T
,
 
a
l
a
n
i
n
e
 
a
m
i
n
o
t
r
a
n
s
f
e
r
a
s
e
;
 
H
B
e
A
g
,
 
h
e
p
a
t
i
t
i
s
 
B
 
e
 
a
n
t
i
g
e
n
;
 
H
B
s
A
g
,
 
h
e
p
a
t
i
t
i
s
 
B
 
s
u
r
f
a
c
e
 
a
n
t
i
g
e
n
;
 
H
B
v
,
 
h
e
p
a
t
i
t
i
s
 
B
 
v
i
r
u
s
;
 
P
C
R
,
 
p
o
l
y
m
e
r
a
s
e
 
c
h
a
i
n
 
r
e
a
c
t
i
o
n
.
entecavir outperformed the   comparator drug. Rates of HBeAg 
loss were 18%–22% and HBeAg seroconversion 15%–21%, 
which were no different from rates seen in the lamivudine arms 
of the trial. Only one study reported on histologic response 
(its primary endpoint), with 72% of entecavir-treated patients 
responding favorably.12
Results at 48 weeks were similar among nucleoside-naïve 
HBeAg-negative patients, though the number of patients 
treated in the Chinese study was small (n = 33).13,14 High rates 
of ALT normalization (78%–94%), undetectable HBV DNA 
by PCR assay (90%–94%), and histologic response (70%) 
were seen. The mean drop in HBV DNA was approximately 
5 log copies/mL.
Phase II and III studies in the more difficult-to-treat lamivu-
dine-refractory population were completed in multinational12,18 
and Asian cohorts.19,20 Week 48 HBV DNA suppression was 
not as robust as seen in naïve patients, with mean decreases 
of about 5 log copies/mL. ALT normalization was seen in 
61%–85% of patients, and HBV DNA undetectability by PCR 
assay in just 19%–33% of subjects at the end of 1 year. Among 
HBeAg-positive patients, HBeAg loss was seen in 10%–11%, 
and HBeAg seroconversion in 4%–8%. Histologic responses 
were seen in 55%–60% of subjects.18,20
The design of the entecavir trials makes determinations 
of efficacy beyond 48 weeks confusing. In most trials, 
patients who were classified as “responders” (in HBeAg-
positive patients: HBV DNA , 0.7 mEq/mL [∼700,000 
copies/mL], loss of HBeAg; in HBeAg-negative patients: 
HBV DNA , 0.7 mEq/mL) were removed from the study 
drug at 48 weeks and monitored off therapy for sustained 
response without the now standard period of consolidation 
therapy following HBeAg seroconversion.23 Nonresponders 
(HBV DNA . 0.7 mEq/mL at week 48) were also discontin-
ued from therapy. Therefore, those continuing on entecavir 
for 2 years and beyond represent a biased cohort of patients 
from which conclusions regarding entecavir efficacy must 
be made with caution. However, published data suggest that 
entecavir maintains virologic suppression and ALT normal-
ization through up to 5 years of treatment, with additional 
cumulative HBeAg seroconversion and a small chance of 
HBV surface antigen (HBsAg) loss.16,17,21,22,24
Compared with other available nucleos(t)ide analogs, 
entecavir achieves more potent HBV DNA suppression than 
all agents except perhaps tenofovir, which is equivalent. 
HBeAg clearance and HBeAg seroconversion are compa-
rable with lamivudine. As with most oral agents, surface 
antigen loss is rare. Comparative efficacies of available 
agents at 1 year are shown in Table 2.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Entecavir resistance
One disadvantage of nucleos(t)ide analogs is development of 
antiviral resistance with prolonged use. Resistance is accom-
panied by virologic and biochemical breakthrough, and, in 
rare cases, hepatic decompensation and death.34,35 Rates of 
lamivudine resistance exceed 70% by year 4 of treatment,36 
limiting its usefulness for first-line therapy. Resistance rates 
for adefovir and telbivudine are lower, yet still clinically 
significant (Figure 1). Tenofovir resistance has not yet been 
well defined but appears to be rare, as no signature mutation 
has been defined and genotypic resistance through 4 years 
of therapy has not been reported.41
Resistance to HBV antivirals is conferred by mutations 
in the HBV polymerase, which render the agent ineffective. 
For lamivudine, the signature mutation is a change in the 
reverse transcriptase at position 204 from methionine to 
valine or isoleucine (rtM204V/I).43 The rtM204I mutation 
also confers resistance to telbivudine.42 Lamivudine-resistant 
patients may develop a compensatory mutation at position 
180 from leucine to methionine (rtL180M), which restores 
viral fitness. Adefovir does not show cross-resistance with 
lamivudine or telbivudine, with its signature resistance muta-
tions a change from asparagine to threonine at position 236 
(rtN236T)44 or alanine to valine or threonine at position 181 
(rtA181V/T).45
Entecavir resistance is unique because it requires up 
to three mutations for full resistance to develop.46 The 
rtM204V/I mutation, lamivudine’s signature mutation, is 
necessary but not sufficient for entecavir resistance, caus-
ing an 8- to 10-fold decrease in susceptibility to entecavir 
compared with wild-type HBV . Additional mutations 
at positions rtI169, rtT184, rtS202, and rtM250 confer 
additional decreases in entecavir susceptibility.46,47 These 
mutations alone have only a minimal impact on entecavir 
efficacy, but in the presence of an rtM204 mutation, the 
addition of one of these mutations leads to a 10- to 250-fold 
decrease in entecavir susceptibility and two mutations to a 
500- to 1000-fold decrease.46,47
The large genetic barrier to resistance has predictably led 
to low observed rates of clinical genotypic entecavir resistance 
in trials of nucleos(t)ide-naïve HBV patients. In the registra-
tion trials of entecavir, rates of genotypic resistance after 
1 year were 0% in both HBeAg-positive and HBeAg-negative 
patients.12,13 A long-term resistance cohort from these trials 
has demonstrated that, after 4 years, cumulative resistance in 
naïve patients was 0.8% and, after 6 years, 1.2%.37   Cumulative 
genotypic resistance rates among lamivudine-refractory 
patients are much higher: 6%, 15%, 36%, 47%, 51%, and 
57% at years 1–6, respectively.37 Although entecavir has been 
studied in   lamivudine-refractory patients, its use as a salvage 
drug in this setting is generally not recommended when other 
options are available, because of these higher resistance rates. 
This demonstrates the superiority of entecavir when used as a 
first-line agent rather than following lamivudine failure, and 
highlights the importance of considering antiviral sequencing 
when selecting initial HBV therapy.
Special populations
Advanced fibrosis, cirrhosis,  
and transplanted patients
Approximately 15% of the subjects enrolled in the registra-
tion trials of entecavir had advanced fibrosis, defined as 
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an Ishak score of 4–6. All patients had compensated liver 
disease. Results in this subgroup of patients were published 
separately.48 For all endpoints examined in the parent studies, 
subjects with advanced fibrosis achieved comparable efficacy 
with the overall study population, including HBeAg-positive, 
HBeAg-negative, and lamivudine-refractory populations. 
Up to 59% of patients experienced an improvement in 
Ishak fibrosis score, which was better than that seen in the 
study population at large. Patients with advanced fibrosis or 
  cirrhosis did not experience any more adverse events than 
the overall study population. No patient discontinued ente-
cavir due to adverse events. There was a single ALT flare in 
the entecavir group. All deaths in the entecavir arm during 
the trial occurred in the subgroup with advanced fibrosis or 
cirrhosis, but no death was deemed related to study drug. 
One patient died from a gastrointestinal bleed secondary to 
a splenic lymphoma, one from hepatocellular carcinoma, 
and one from multiorgan failure from diabetes mellitus and 
cirrhosis.48
Experience with entecavir in decompensated cirrhosis has 
shown improvements in Child–Turcotte–Pugh (CTP) scores 
(from 8.1 to 6.6) and Model for End-stage Liver Disease 
(MELD) scores (from 11.1 to 8.8) after 1 year of therapy.49 
In this single-center study, all patients were nucleos(t)ide 
naïve, as well as naïve to interferon. Compared with patients 
with compensated liver disease, those with decompensated 
cirrhosis had comparable rates of undetectable HBV DNA 
at month 12 (89.1% versus 78.5%, P = 0.104), HBeAg sero-
conversion (22.2% versus 24.4%, P = 0.812), HBeAg loss 
(48.1% versus 41.1%, P = 0.512), and ALT normalization 
(76.4% versus 75.0%, P = 0.535).49 There were no virologic 
breakthroughs on therapy. The cumulative incidence of mor-
tality was 17% and the cumulative incidence of HCC or liver 
transplant was 6.9% among the decompensated cirrhotics, 
but no control group was reported.
Entecavir has also been compared with adefovir in a 
Phase IIIb study in subjects with evidence of hepatic dec-
ompensation.50 At baseline, the mean HBV DNA in the 
entecavir group was 7.53 log copies/mL, mean MELD 17.1, 
and mean CTP score 8.81. Thirty-six percent of subjects 
were lamivudine resistant, and 54% were HBeAg positive. 
In an interim analysis of the first 100 patients to complete 
96 weeks of treatment, entecavir had a statistically signifi-
cant higher rate of HBV DNA , 300 copies/mL at week 
48 compared with adefovir (57% versus 20%, respectively, 
P , 0.0001). Entecavir also had higher rates of ALT nor-
malization (63% versus 46%, P = 0.0425) at week 48. Rates 
of HBeAg loss (11% versus 18%), HBeAg seroconversion 
(6% versus 10%), and HBsAg loss (5% versus 0%) were not 
  statistically different. As shown in the prior study, MELD 
scores improved by −2.6 in the entecavir group. Thirty-five 
percent of entecavir-treated patients had a reduction in their 
CTP score by two or more points at week 48. Serious adverse 
events occurred in over 65% of both treatment groups, but 
the details of these events were not reported. Adverse events 
led to drug discontinuation in 7% of entecavir patients and 
6% of adefovir patients. Further follow-up of these patients 
is needed to determine the effects of antivirals on patients’ 
mortality and development of HCC. Although no major 
events were reported in these trials of entecavir in decom-
pensated patients, caution is advised with its use in these 
fragile patients, as later case reports demonstrated fatal 
lactic acidosis.
There is little published information on entecavir in the 
post-liver transplant population. A single-center retrospec-
tive case-control study of 30 patients treated with entecavir 
compared with lamivudine showed that entecavir achieved 
undetectable HBsAg levels earlier than lamivudine (median 
3 days versus 5 days).51 There were fewer HBV recurrences 
in the entecavir group (0% versus 11.1% in the lamivudine 
group), but cumulative survival rates after 30 months were 
similar in both groups (actuarial survival 81%). Larger, 
prospective trials are needed in this population, but the 
limited data available are favorable. Given the long-term 
therapy necessary post-transplant, the low resistance rates 
associated with entecavir make it an attractive option for 
post-transplantation prophylaxis.
HIv
Entecavir has been studied in HIV-positive patients failing 
lamivudine-containing antiretroviral regimens.52 Ninety-five 
percent of these patients had lamivudine resistance at base-
line, and the 1 mg dose of entecavir was used. At 48 weeks, 
HBV DNA decreased by 4.2 log copies/mL, and 8% of 
subjects had an undetectable HBV DNA. ALT normalization 
occurred in 37%, and only 2% achieved HBeAg loss/HBeAg 
seroconversion.
During clinical development, entecavir was not shown to 
have any activity against HIV . It therefore became the treat-
ment of choice for HIV patients requiring treatment of HBV 
who did not meet criteria for antiretroviral therapy for HIV . 
Following its approval, reports of entecavir’s effects on HIV 
replication and resistance were reported.53,54 In these reports, 
entecavir decreased HIV viral loads by about 1 log copies/mL. 
More sensitive in vitro assays using primary CD4+ T cells 
rather than transformed cell lines confirmed entecavir Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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  inhibition of HIV in the low nanomolar range.53 In addition 
to effects on HIV viral load, entecavir also selected for the 
methionine to valine mutation at position 184 (M184V) of 
the HIV reverse transcriptase, which is the signature muta-
tion for HIV resistance to lamivudine. This occurred in three 
patients in the absence of any exposure to antiretrovirals.54 
Because of these reports, entecavir is not recommended as 
monotherapy in HIV/HBV-coinfected patients who are not 
receiving a fully active antiretroviral regimen. Most recent 
HIV treatment guidelines from the United States Department 
of Health and Human Services55 and the International AIDS 
Society-USA55,56 list active chronic HBV as an indication 
for antiretroviral therapy in HIV patients, regardless of CD4 
count or HIV viral load. This recommendation stems in part 
from these findings related to entecavir activity.
Adverse effects
During the Phase III trials of entecavir, there were no adverse 
effects of the drug that occurred more often than with the 
comparator drug. The most common adverse events were 
elevations in ALT, which were associated in all cases with 
reductions in HBV DNA.12,13 In most cases, these were self-
limiting with continued treatment with entecavir. Among 
nucleoside-naïve HBeAg-positive patients, ALT flares over 
twice baseline and .10 times upper limit of normal (ULN) 
occurred in 3% of entecavir-treated patients, and ALT flares 
over twice baseline and more than five times ULN occurred in 
10% of subjects.12 These numbers in naïve HBeAg- negative 
subjects were ,1% and 2%, respectively.13 Discontinuation 
due to adverse events was 2% or less in both studies at 1 year. 
There were no unusual adverse effects during the Phase II 
and III trials that were concerning.
Experience with nucleoside analogs in the treatment of 
HIV demonstrated an association with certain drugs and lactic 
acidosis variably accompanied by hepatic steatosis, pancrea-
titis, peripheral neuropathy, and myopathy. The dideoxy-
nucleotide analogs were particularly implicated (didanosine 
[ddI], zalcitabine [ddC]). Development of an investigational 
drug for HBV, fialuridine (FIAU), was halted after seven 
patients in a Phase II trial developed severe lactic acidosis 
after a minimum of 9 weeks of therapy.57 Five patients in 
the study died, and two survived only after   emergent liver 
transplant. All seven had pancreatitis with severe lactic aci-
dosis and hepatic failure. Histologic examination showed 
marked macro- and microvesicular steatosis and cholestasis. 
Mitochondrial anatomy was distinctly abnormal on electron 
microscopy. In part because of these clinical reports, all 
nucleos(t)ide analogs, including entecavir, carry a black-box 
warning against the occurrence of lactic acidosis and severe 
hepatomegaly with steatosis.
Further study into the mechanisms for both HIV antiret-
roviral and FIAU toxicity implicate damage to mitochondria 
as the reason for metabolic perturbation.58–60 In addition 
to inhibition of the viral polymerase, nucleoside analogs 
also inhibit the polymerase function of the human DNA 
polymerase-γ, which is responsible for replication of mito-
chondrial DNA.60 Depletion of mitochondrial DNA leads to 
mitochondrial dysfunction, as synthesis of proteins essential 
for oxidative phosphorylation is inhibited. Mutations in mito-
chondrial DNA and oxidative stress within the mitochondria 
may also contribute to this dysfunction. Electron leakage 
from the electron transport chain occurs with disruption of 
oxidative phosphorylation, increasing production of reactive 
oxygen species.60
In vitro studies of entecavir did not show any evidence for 
mitochondrial toxicity.61 Incubation of hepatoma HepG2 cells 
with entecavir at 10 times maximum concentration produced 
no nonspecific cell cytotoxicity. Entecavir also did not affect 
extracellular lactate levels at the highest concentrations and 
durations tested. In assays of mitochondrial DNA, levels were 
not decreased on exposure to entecavir when compared with 
controls. Even at 100 times achievable concentrations in vivo, 
there were no changes in mitochondrial protein levels. Assays 
to assess DNA polymerase-γ showed that entecavir did not 
utilize or inhibit function.
Despite these in vitro studies, postmarketing case reports 
of severe lactic acidosis during treatment with entecavir 
were published.62,63 In the first report, entecavir was used in 
combination with adefovir to treat a newly recognized HBV 
patient who developed a severe flare of hepatitis following 
chemotherapy for chronic lymphocytic leukemia.63 At the 
time of treatment initiation, his MELD score was approxi-
mately 24. His ALT was 3521 U/L, AST 2853 U/L, and 
bilirubin 20.9 mg/dL. After 10 days of combination therapy, 
he presented with dyspnea, hypoxia, and profound metabolic 
lactic acidosis with a lactate level of 9.5 mEq/L, pH 6.95, 
and carbon dioxide level 8 mmol/L. Entecavir and adefovir 
were discontinued. Despite aggressive measures, the patient 
expired within 24 hours of admission.
A second report describes a case series of 16 patients 
with advanced liver disease/decompensated cirrhosis treated 
with entecavir, of whom five developed lactic acidosis.62 
In three cases, the syndrome was severe, and one of these 
cases died. Of the severe cases, lactic acidosis developed at 
5 days, 8 days, and 8 months after initiation of entecavir. 
One of these cases was a post-liver transplant patient with Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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recurrent HBV . Two additional patients had less severe   lactic 
acidosis, which remained compensated. They developed 
symptoms at 4 and 31 days after starting entecavir therapy. 
In this series, all of the patients who developed lactic acidosis 
had an MELD score greater than 22 at the time of entecavir 
initiation. None of the patients whose MELD was lower than 
18 developed lactic acidosis.
Neither of these reports provided histologic or   microscopic 
evidence of mitochondrial damage. Only one patient in the 
second series was reported to have hepatic steatosis. Whether 
these reports of lactic acidosis represent manifestations 
of mitochondrial toxicity cannot be determined, although 
  phenotypically they are suspicious. Of note, toxicity occurred 
much earlier in treatment than is usually seen with mitochon-
drial toxicity with other nucleoside analogs, suggesting a 
possible alternative mechanism for the lactic acidosis seen 
in these cases. These reports are heterogeneous, and a clear 
association with entecavir has not been well established. 
Entecavir is generally considered safe in decompensated 
cirrhosis, and both the American Association for the Study 
of Liver Diseases (AASLD) and European Association for 
the Study of the Liver (EASL) guidelines recommend it in 
this setting.
Use of entecavir in clinical practice
From the data discussed above, entecavir has been proven 
to potently suppress HBV replication with low rates of 
  genotypic resistance even with long-term therapy in the 
nucleos(t)ide-naïve patient. In lamivudine-refractory 
patients, its success rate is compromised, illustrating the 
importance of drug sequencing when considering initial 
HBV therapy. Several professional societies around the 
world have made recommendations regarding initial therapy, 
taking these factors into consideration. The AASLD recom-
mends entecavir or tenofovir as first-line oral agents for 
nucleos(t)ide-naïve patients, as both combine potency and 
low resistance rates.23 Recommendations from the EASL are 
concordant.64 The Asian Pacific Association for the Study of 
the Liver considers all agents to be first line, recognizing that 
the higher cost of entecavir and tenofovir may be prohibitive 
in some cases.65 Therefore, lamivudine remains a first-line 
option in this setting. Finally, the US   Treatment Algorithm66 
also recommends entecavir or tenofovir as first-line agents 
but describes a “road-map” approach, whereby therapy is 
modified at week 24 or 48 as determined by on-therapy 
virologic response. Patients who fail entecavir should be 
switched to tenofovir or tenofovir–emtricitabine according 
to this algorithm.
For patients who already express lamivudine resistance, 
entecavir is not the optimal salvage drug, as entecavir 
resistance develops more quickly. Telbivudine is also cross-
resistant, and patients failing this drug are also not good 
entecavir candidates. For patients failing lamivudine or 
telbivudine, tenofovir is a better alternative. For failures of 
adefovir or tenofovir, entecavir is predicted to maintain full 
activity and is a reasonable salvage choice.
Summary
The approval of entecavir in 2005 began a new era in the 
treatment of HBV where long-term virologic suppression 
was both realistic and safe. The low risk of entecavir resis-
tance in naïve patients, in part due to its rapid and potent 
  suppression of HBV DNA, makes it an optimal choice for the 
initial   therapy of both HBeAg-positive and   HBeAg-negative 
patients. It requires three mutations to develop full resis-
tance, the first of which is selected by lamivudine; hence, 
its activity is reduced in patients with genotypic lamivudine 
  resistance. This is partly overcome by the use of a larger 
dose in   lamivudine-refractory patients. There are few 
adverse effects associated with entecavir, although fatal 
cases of lactic acidosis have been reported with its use in 
  decompensated   cirrhotics, particularly when the MELD score 
exceeds 22. It should be used with caution in this   population. 
Its efficacy in HIV/HBV coinfected patients has been estab-
lished, although it should not be used without a fully sup-
pressive antiretroviral regimen, as anti-HIV activity has been 
described in vitro and in vivo. Its impact on end-stage liver 
disease and mortality has yet to be delineated, as it is yet too 
early to see the benefits of long-term viral suppression.
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